Jushi’s CEO joins NICI for an all-new interview to give you the inside track on its national expansion plans…

One of the most pressing questions I keep seeing from our community here at the National Institute for Cannabis Investors (NICI) has been:

Is Jushi Holdings Inc. (OTC: JUSHF) still a good investment?

My answer is yes. Absolutely.

I laid out my full reasoning in this recent episode of Office Hours, which you can click here to watch.

But today, I want to dive deeper into one of the major indicators that there’s still plenty of money to be made from Jushi – and that is its expansion into lucrative key markets.

Each time a multistate operator (MSO) expands to a new state, it grows its profit potential exponentially by gaining access to a whole new mass of potential customers. That’s what Jushi is doing with its acquisition of Nature’s Remedy in Massachusetts.

This acquisition included full vertical integration for Jushi in Massachusetts as the new owner of two dispensaries in Millbury and Tyngsborough and a 50,000-square-foott cultivation and processing facility in Lakeville.

Since recreational sales kicked off in early 2018, Massachusetts consumers have already spent $2 billion, and they’re expected to add another $1.4 billion to that total in 2021.

Entry into this market is a major victory for Jushi – one that isn’t currently reflected by the company’s stock price.

So in order to paint you a more accurate portrait of Jushi’s performance over the last few months, I sat down with its CEO Jim Cacioppo for an exclusive one-on-one interview.

You’ll get to hear from him directly about all of Jushi’s recent acquisitions and milestones so you can emerge with a better understanding of why I’m still so confident in this company’s ability to make you money in the future.

And because I didn’t want to skip over anything important, we’re breaking this interview up into two parts.

Part one of our conversation is available now, so make sure you tune in here…

Current NICI Membership subscribers already have access to my full interview with Jim right here, in addition to a hand-picked model portfolio of the best pot stocks to own. If you’d like to dive into the full interview now, and gain access to those recommendations, you can click here to join.

I’ll be sending out part two tomorrow, so keep an eye on your inbox.

To your investing success,

Danny Brody
Executive Director, National Institute for Cannabis Investors


Comments

2 responses to “Jushi CEO Jim Cacioppo Is Giving You the Inside Track on His Company’s East Coast Takeover (Part One of Exclusive Interview)”

  1. Heard a price target on Jushi, of over $30 per share.
    Heard other target(s) around $4.50 per share.
    Can you explain the vast difference in the two analysts?

    • Hi Joseph,

      One thing to consider with price targets is when they were released and if there was a time frame given. For Jushi, a $30 target could be for 12-18 months or more, and it may be dependent on the analyst believing some form of legalization would pass to send the stock price that high and certain other metrics would need to be hit in a best case scenario to reach that price. Jushi was trading for $2.49 in the past 52 weeks, so that $4.50 price target may have been released when the stock was trading around $2.

Leave a Reply

Your email address will not be published. Required fields are marked *